Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
129 hedge funds and large institutions have $579M invested in Orexigen Therapeutics, Inc. in 2014 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 48 increasing their positions, 41 reducing their positions, and 19 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 41
0% more funds holding
Funds holding: 129 → 129 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 19
0% less call options, than puts
Call options by funds: $11.7M | Put options by funds: $11.7M
4% less capital invested
Capital invested by funds: $605M → $579M (-$26M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.5M |
| 3 |
CPIM
Columbia Partners Investment Management
Alexandria,
Virginia
|
+$5.22M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.95M |
| 5 |
CC
CQS Cayman
Camana Bay, Grand Cayman,
Cayman Islands
|
+$3.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$10.8M |
| 2 |
QF
QVT Financial
New York
|
-$8.6M |
| 3 |
First Manhattan
New York
|
-$8.14M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
-$4.8M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$3.05M |
OREX Hedge Fund Activity: Q2 2014 in Review
129 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q2 2014, worth a combined $579M — down 4.3% from $605M a quarter earlier.
Fund positioning in OREX was balanced in Q2 2014: 19 funds opened new positions, 19 closed out, 48 added to existing stakes and 41 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $17.5M. The largest seller was Millennium Management, cutting an estimated $10.8M.
- 129 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q2 2014, unchanged from Q1 2014.
- Funds reported $579M of Orexigen Therapeutics, Inc. stock for Q2 2014, down 4.3% quarter-over-quarter.
- 19 funds opened new Orexigen Therapeutics, Inc. positions in Q2 2014 and 19 closed out, a net change of 0 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q2 2014 was Fidelity Investments, an estimated $17.5M added.
- The largest Orexigen Therapeutics, Inc. seller in Q2 2014 was Millennium Management, an estimated $10.8M sold.
Based on aggregated 13F filings for Q2 2014.